How does KPV work?

KPV is the C-terminal tripeptide of alpha-MSH, sequence lysine-proline-valine. This site's profile says it enters cells and suppresses pro-inflammatory NF-kB signaling. Molecular weight is 342.4 daltons. Half-life is listed as short. This site's review found no published human trial. The FDA removed it from the Category 2 compounding list in April 2026; a July 2026 advisory vote, 8 to 6, recommended it for compounding against the reviewers. That vote is advisory and is not an approval. The cited work is mouse colitis and cell culture: nanomolar KPV inhibited NF-kappaB and MAP kinase signaling, and oral KPV reduced DSS- and TNBS-induced colitis via the PepT1 transporter. Those animal findings do not transfer into a counted human gut-healing mechanism. This FAQ does not invent a human mechanism. Full record at /compounds/kpv.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of healing and recovery peptides. BPC-157, TB-500, GHK-Cu, and the tissue repair family, including what actually has human data.